106511-73-3

Basic information

• Product Name: 5-benzyl-4-(4-methoxyphenyl)thiazol-2-amine
• Synonyms: 5-benzyl-4-(4-methoxyphenyl)thiazol-2-amine
• CAS NO: 106511-73-3
• Molecular Weight: 296.393
• Mol File: 106511-73-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-benzyl-4-(4-methoxyphenyl)thiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-benzyl-4-(4-methoxyphenyl)thiazol-2-amine(106511-73-3)
• EPA Substance Registry System: 5-benzyl-4-(4-methoxyphenyl)thiazol-2-amine(106511-73-3)

Safety Data

• Hazardous Substances Data: 106511-73-3(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 22966-19-4 trans-4'-methoxychalcone 
• 5739-38-8 1-(4-methoxyphenyl)-3-phenylpropan-1-one 
• 106511-71-1 2-Bromo-1-(4'-methoxyphenyl)-3-phenyl-1-propanone 
• 17356-08-0 thiourea 

Downstream Products

• 1446017-81-7 5-benzyl-4-(4-methoxyphenyl)-N-(naphthalen-2-ylmethyl)thiazol-2-amine 
• 1446017-82-8 5-benzyl-4-(4-methoxyphenyl)-N-(pyridin-3-ylmethyl)thiazol-2-amine 
• 1446017-78-2 5-benzyl-N-(furan-2-ylmethyl)-4-(4-methoxyphenyl)thiazol-2-amine 
• 1446017-84-0 5-benzyl-4-(4-methoxyphenyl)-N-(3,4,5-trimethoxybenzyl)thiazol-2-amine 
• 1446017-75-9 4-((5-benzyl-4-(4-methoxyphenyl)thiazol-2-ylamino)methyl)-2-methoxyphenol 
• 1621006-44-7 2-((5-benzyl-4-(4-methoxyphenyl)thiazol-2-ylamino)methyl)-4-nitrophenol 
• 1446017-83-9 5-benzyl-N-(2,6-dichlorobenzyl)-4-(4-methoxyphenyl)thiazol-2-amine 
• 1446017-89-5 5-benzyl-4-(4-methoxyphenyl)-N,N-dimethylthiazol-2-amine 
• 1446017-93-1 4-(5-benzyl-2-(diethylamino)thiazol-4-yl)phenol 
• 1446017-90-8 5-benzyl-N,N-diethyl-4-(4-methoxyphenyl)thiazol-2-amine 
• 1446017-86-2 4-((5-benzyl-4-(4-methoxyphenyl)thiazol-2-ylamino)methyl)benzonitrile 

Relevant articles and documents

2,4,5-Trisubstituted thiazole derivatives: A novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase

Novel 2,4,5-trisubstituted thiazole derivatives (TSTs) were designed and synthesized as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Among the thirty-eight synthesized target compounds, thirty TSTs showed potent inhibition against HIV-1 replication in wild type HIV-1 at submicromolar concentrations (from 0.046 to 9.59 μM). Compounds 21, 23 and 24 were also tested on seven NNRTI-resistant HIV-1 strains, and all exhibited inhibitory effects with fold changes in IC50 ranging from 2.6 to 111, which were better than those of nevirapine (15.6-fold-371-fold). Docking simulations of compound 24 revealed a reasonable mechanism for the binding mode, and three-dimensional quantitative structure activity relationship (3-DQSAR) studies on this novel series of TST further elucidated the structure-activity relationship (SAR). The results suggested the great potential of TSTs as a novel class of NNRTIs with antiviral efficacy and a good resistance profile.

TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF

The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.